SCHEMBL1198613

SCHEMBL1198613

O=C(O)c1cnn(Cc2nc(-c3cc(CCc4cccnc4)cc(C(F)(F)F)c3)cs2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
EGLN1 Q9GZT9 2/20 0.37
ABL1 P00519 2/20 0.36
BCR P11274 2/20 0.36
EIF4E P06730 1/20 0.36
CFTR P13569 1/20 0.36
KIT P10721 1/20 0.36
KDM4C Q9H3R0 1/20 0.35
KLKB1 P03952 1/20 0.35
SORT1 Q99523 1/20 0.35
PTGER1 P34995 1/20 0.35
GPBAR1 Q8TDU6 1/20 0.35
RAB9A P51151 3/20 0.35
NPC1 O15118 2/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1199101 0.92 ALDH1A1 (0.45) ALDH1A1KDM4EMEN1KMT2AEGLN1
SCHEMBL12890246 0.88 KDM4E (0.44) ALDH1A1KDM4EMEN1KMT2AEGLN1
SCHEMBL12876201 0.87 KLKB1 (0.40) ALDH1A1KMT2AEIF4EKLKB1RAB9A
SCHEMBL1198589 0.87 MMP13 (0.40) ALDH1A1KDM4EMEN1KMT2AEGLN1
SCHEMBL1198742 0.87 ALDH1A1 (0.42) ALDH1A1KDM4EMEN1KMT2AEGLN1
SCHEMBL1198758 0.87 ALDH1A1 (0.39) ALDH1A1KDM4EMEN1KMT2AEGLN1
SCHEMBL1197745 0.86 ALDH1A1 (0.42) ALDH1A1KDM4EMEN1KMT2AEGLN1
Trifluoroacetic Acid SCHEMBL2863073 0.85 GPR132 (0.39) ALDH1A1KDM4EMEN1KMT2AEGLN1
SCHEMBL1198676 0.85 MEN1 (0.43) ALDH1A1KDM4EMEN1KMT2AEGLN1
SCHEMBL1198794 0.85 MEN1 (0.45) ALDH1A1KDM4EMEN1KMT2AEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A ALDH1A1 1037/4885KDM4E 1877/4885MEN1 2661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.